Improving Diagnostic Safety through STeatosis Identification, Risk stratification, and Referral in the ED (STIRRED)
Project Number1R01HS029777-01
Contact PI/Project LeaderKONTRICK, AMY V Other PIs
Awardee OrganizationNORTHWESTERN UNIVERSITY AT CHICAGO
Description
Abstract Text
PROJECT ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is a public health crisis affecting one third of the US adult population.
NAFLD is an obesity related disease with serious health and quality of life consequences including type 2
diabetes, cirrhosis, liver cancer, and cardiovascular disease. Despite serious threats to health and wellbeing,
NAFLD has not received the same attention as other cardiometabolic diseases like type 2 diabetes. In addition,
NAFLD is often asymptomatic and patients are frequently diagnosed when hepatic steatosis is reported as an
incidental finding on imaging studies or a patient develops advanced liver disease. Our prior work found
hepatic steatosis reported in just under 10% of written radiology reports. Unfortunately, lack of awareness often
leads to hepatic steatosis being overlooked by providers and unreported to patients leading to delays in
diagnosis and referral to specialty care. Our recent survey revealed only 13% of providers always reported this
finding to patients. This project, Improving Diagnostic Safety through STeatosis Identification, Risk
stratification, and Referral pathway in the ED (STIRRED), proposes to improve diagnostic safety by
ensuring that patients receive timely notification of the new finding and referral to follow up care. To date, we
have developed the building blocks for the STIRRED CDSS by employing natural language processing and
machine learning to identify hepatic steatosis in written emergency department (ED) radiology reports and
combine it with common clinical data and comorbidities in the electronic health record to create an
individualized risk profile and follow up recommendations for patients with suspected (NAFLD). Providing risk
stratified appropriate referrals for patients from the ED will increase diagnosis of NAFLD, enable those deemed
high risk for advanced liver disease to receive specialist referral and begin the important process of cancer
screening and intervention to improve steatosis. Communicating this incidental imaging finding and initiating
referral from the ED will enable linkage to care to improve health outcomes and reverse or slow disease
progression for those at all risk levels. While the groundwork for this intervention has been laid, for STIRRED
to be successful, it must be both refined further and implemented thoughtfully. Through Aim 1 and 2, we will
seek to: 1) determine the barriers, facilitators, and additional strategies to implement the STIRRED CDSS, and
2) conduct usability testing of the STIRRED CDSS. Upon finalizing the optimized STIRRED CDSS and
implementation plan, we seek to: 3) evaluate STIRRED across a large health system. This work will be led by
a team of experienced researchers with expertise in clinical trials, risk communication, patient communication,
diagnostic uncertainty, hepatic steatosis and NAFLD, incidental findings, implementation science, and health
services research. Completion of these aims will result in tools to improve care transitions and diagnostic
safety for patients with hepatic steatosis and suspected NAFLD. Findings will inform future work to implement
STIRRED in EDs nationally and develop ED-based interventions for patients with suspected NAFLD.
Public Health Relevance Statement
PROJECT NARRATIVE
Hepatic steatosis is a common radiographic “incidental finding” that is overlooked and underreported to
patients. We developed a clinical decision support system using machine learning and natural language
processing that will prompt reporting to patients and provide ED clinicians risk stratified follow-up care
recommendations. Data on both the implementation and effectiveness of our intervention resulting from this
trial will inform future use with a goal of ultimately improving diagnostic safety and outcomes for patients with
hepatic steatosis.
No Sub Projects information available for 1R01HS029777-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01HS029777-01
Patents
No Patents information available for 1R01HS029777-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01HS029777-01
Clinical Studies
No Clinical Studies information available for 1R01HS029777-01
News and More
Related News Releases
No news release information available for 1R01HS029777-01
History
No Historical information available for 1R01HS029777-01
Similar Projects
No Similar Projects information available for 1R01HS029777-01